|
著者: Keith Edwards, Donald Royall, Linda Hershey, David Lichter, Ann Hake, Martin Farlow, Florence Pasquier, Stewart Johnson
雑誌名: Dement Geriatr Cogn Disord. 2007;23(6):401-5. doi: 10.1159/000101512. Epub 2007 Apr 3.
Abstract/Text
BACKGROUND: Dementia with Lewy bodies (DLB) is a common dementia of the elderly. A significant cholinergic deficit has been demonstrated that may be responsive to treatment by cholinesterase inhibitors (ChEIs). METHODS: A 24-week, open-label study was designed to assess the efficacy and safety of a ChEI, galantamine, in 50 patients with DLB. RESULTS: This study showed beneficial effects with galantamine in 2 of the 3 primary efficacy parameters. The scores on the Neuropsychiatric Inventory (NPI-12) improved by 8.24 points from baseline (p = 0.01) especially in visual hallucinations and nighttime behaviors (p = 0.004). The scores on the Clinician's Global Impression of Change improved by 0.5 points from baseline (p = 0.01). The third primary efficacy parameter, the Cognitive Drug Research Computerized Cognitive Assessment System, was unchanged from baseline. Adverse events were generally mild and transient. CONCLUSION: Galantamine appears to be an effective and safe therapy for patients with DLB.
PMID 17409748 Dement Geriatr Cogn Disord. 2007;23(6):401-5. doi: 10.1159/000101512. Epub 2007 Apr 3.
|